According to a report by Wall Street Journal (WSJ), China will supply a coronavirus vaccine candidate which is developed by a Sinopharm (A unit of China National Pharmaceutical Group) The report said Sinopharm is all set to work with the University of Karachi for the trials of the vaccine. Pakistan will receive enough doses of the candidate vaccine to help out one-fifth of the population.
The starting doses will be given to the people with serious cases of coronavirus including some elderly healthcare workers. WSJ report also added the vaccine is proven safe according to the researchers and will play a beneficial role in early trials. The candidate vaccine is being tested on several thousand people to see the efficiency to make it worthy enough to win regulatory approval.
This vaccine triggers antibody responses in the affected people without causing any serious side effects. 320 people were declared recovered in phases 1 and 2 of the trials. In about three months phase 3 testing is expected to be completed and the vaccine could be ready by the end of the year. Earlier, in a letter sent to Maj Gen Dr. Aamer Ikram, the Executive Director of NIH Islamabad by the general manager of Sinopharm International Corporation, Li Can Expressed a hope that “A successful clinical trial in Pakistan will make it one of the first few countries for the launch a Covid-19 vaccine.”
